SPARC.BO - Sun Pharma Advanced Research Company Limited

BSE - BSE Real Time Price. Currency in INR

Sun Pharma Advanced Research Company Limited

17-B, Mahal Industrial Estate
Off Mahakali Caves Road Andheri (East)
Mumbai 400093
India
91 22 6645 5645
http://www.sparc.life

SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic
Full-time employees427

Key executives

NameTitlePayExercisedYear born
Mr. Dilip Shantilal ShanghviChairman & MDN/AN/A1955
Mr. Chetan RajparaChief Financial Officer13.28MN/AN/A
Mr. Debashis DayCompliance Officer & Company Sec.3.13MN/AN/A
Mr. Anil RaghavanChief Exec. OfficerN/AN/AN/A
Dr. Subhas BhowmickSr. VPN/AN/A1956
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in INR.

Description

Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally. The company develops new chemical entities or reformulated products based on its proprietary novel drug delivery systems. Its core therapeutic areas of interest include oncology, inflammation, and neurodegenerative diseases, as well as abuse deterrent formulations. The company offers Levetiracetam ER for epilepsy; and Xelpros eye drops for Glaucoma. It is also developing Taclantis for the treatment of cancer; salmeterol-fluticasone dry powder inhaler for use in asthma and COPD; Baclofen GRS for spasticity; Brimonidine OD for glaucoma and ocular hypertension; and SDN-037 steroid eye drops used for the treatment of pain and inflammation following ocular surgery, and other inflammatory ocular conditions. In addition, the company engages in the development of SCO-088, a Bcr–Abl kinase inhibitor for treatment resistant chronic myelogenous leukaemia (CML); SDN-021, an abuse deterrent formulation; and SCD-044, a S1P receptor-1 agonist, which uses lymphocyte trafficking to treat auto-immune disorders. Further, it develops SCC–138 for Parkinson's disease; SDN–118, a formulation for treating depression; SDD-098 to treat acne; and SDE-124, a sub cutaneous injection of GLP-1 receptor agonists, as well as SCO-125 to treat CML. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet to develop S1P receptor 1 agonist for autoimmune disorders; and HitGen to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Pvt. Ltd.

Corporate governance

Sun Pharma Advanced Research Company Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.